Utomilumab (** Investigational drug (no approved brand names; also known as PF-05082566) **)
Immunotherapy
Description
Utomilumab is under investigation for the treatment of various cancers including colorectal cancer (CRC); it has shown promise in preclinical and early clinical studies by enhancing immune responses against tumors; however, its use in CRC is still experimental and no brand name has been approved yet.
Mechanism of Action
Utomilumab is a fully human IgG1 monoclonal antibody that binds to the CD137 receptor, also known as 4-1BB, which is expressed on activated T cells and NK cells; it acts by enhancing T cell proliferation and cytokine production, thereby amplifying immune responses.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | ** Investigational drug (no approved brand names; also known as PF-05082566) ** |
| Category | Immunotherapy |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.